Frederick B. Oleson
Corporate Officer/Principal bei CUBIST PHARMACEUTICALS INC
Profil
Frederick B.
Oleson is currently the Vice President-Non-Clinical Development at Cubist Pharmaceuticals LLC since 1997.
Prior to this, he worked as the Director-Toxcology & Preclinical Pharmacology at Biogen MA, Inc. from 1992 to 1997, and as the Director-Investigative Toxicology at Bristol Myers Squibb Co. from 1983 to 1992.
He also briefly worked as the Director-Preclinical Research at AutoImmune, Inc. in 1997.
Oleson completed his undergraduate degree at Princeton University and his graduate and doctorate degrees at Harvard T.H.
Chan School of Public Health.
Aktive Positionen von Frederick B. Oleson
| Unternehmen | Position | Beginn |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.1997 |
Ehemalige bekannte Positionen von Frederick B. Oleson
| Unternehmen | Position | Ende |
|---|---|---|
AutoImmune, Inc.
 AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Corporate Officer/Principal | 01.06.1997 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.1997 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1992 |
Ausbildung von Frederick B. Oleson
| Princeton University | Undergraduate Degree |
| Harvard T.H. Chan School of Public Health | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
AutoImmune, Inc.
AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
